Get the Stockscreener App
21.72
1.35%
0.29
After Hours:
21.73
0.01
+0.05%
Acadia Pharmaceuticals Inc stock is traded at $21.72, with a volume of 1.12M.
It is up +1.35% in the last 24 hours and down -2.12% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
See More
Previous Close:
$21.43
Open:
$21.72
24h Volume:
1.12M
Relative Volume:
0.64
Market Cap:
$3.72B
Revenue:
$1.10B
Net Income/Loss:
$375.65M
P/E Ratio:
9.8894
EPS:
2.1963
Net Cash Flow:
$113.59M
1W Performance:
+0.42%
1M Performance:
-2.12%
6M Performance:
-18.30%
1Y Performance:
-0.23%
1-Day Range:
$21.48
$21.85
1-Week Range:
$20.75
$21.95
52-Week Range:
$19.69
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
21.72 | 3.67B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
441.74 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.73 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
842.27 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.64 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.69 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-23-26 | Upgrade | Mizuho | Neutral → Outperform |
| Oct-21-25 | Initiated | Citigroup | Buy |
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
ACADIA Stock Climbs After Hours as Biotech Rally Shifts Focus to Its Next Big Drug Readout - Bez Kabli
Baker funds tied to ACAD (ACAD) report RSU and stock option grants - Stock Titan
Technical Reactions to ACAD Trends in Macro Strategies - Stock Traders Daily
ACAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ACADIA Pharmaceuticals (ACAD) director receives new RSUs and stock option grant - Stock Titan
ACADIA (NASDAQ: ACAD) director Adora Ndu exercises RSUs and receives new option, RSU grants - Stock Titan
ACADIA (NASDAQ: ACAD) director receives RSUs and $21.66 stock options - Stock Titan
ACADIA (NASDAQ: ACAD) director granted RSUs, options and exercises into shares - Stock Titan
ACADIA (ACAD) director Garofalo exercises RSUs and receives new option, RSU awards - Stock Titan
ACADIA (NASDAQ: ACAD) director granted RSUs and stock options - Stock Titan
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Acadia Shareholders Approve Directors, Executive Pay and Equity Plan - The Globe and Mail
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $38 - Moomoo
Acadia Pharmaceuticals (NASDAQ: ACAD) investors approve 5.2M-share boost to 2024 equity plan - Stock Titan
Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock - Benzinga
Biopharmas look to China, elsewhere for partnerships, R&D - MSN
Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus
Acadia principal accounting officer Kihara sells $114,393 stock - Investing.com UK
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
ACADIA Pharmaceuticals (ACAD) Holds Near Support as Price Action ConsolidatesDiagonal Spread Trade - thelegaladvocate.com
ACADIA Pharmaceuticals targets $1B brand opportunity as key neuropsychiatry data looms - MSN
Form 144 lists 3,857 performance shares and ESPP lots for ACAD (NASDAQ: ACAD) - Stock Titan
Acadia Pharmaceuticals (ACAD) lags Q1 earnings and revenue estimates - MSN
Acadia boosts ‘More To Parkinson's’ campaign with Ryan Reynolds, Parkinson’s voices - Fierce Pharma
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle By Investing.com - Investing.com Canada
Trading the Move, Not the Narrative: (ACAD) Edition - Stock Traders Daily
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts - Sahm
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle - Investing.com UK
ACAD Technical Analysis | Trend, Signals & Chart Patterns | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACAD: Remlifanserin advances in ADP, NUPLAZID expands reach, and DAYBUE STIX boosts patient persistence - TradingView
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth - Barchart.com
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story - simplywall.st
Acadia Pharmaceuticals (ACAD) CEO Highlights Global R&D Partners - GuruFocus
Biopharmas look to China, elsewhere for partnerships, R&D (ACAD:NASDAQ) - Seeking Alpha
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus - AD HOC NEWS
Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story - Yahoo Finance
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady By Investing.com - Investing.com Australia
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady - Investing.com
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.89%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):